As the biology of the CCL17/CCL22-CCR4 chemokine–receptor axis is being further elucidated, interest in its constituent molecules as potential therapeutic targets for the treatment of allergies, autoimmune diseases, and cancer has been growing. The gene discussed is CCR4; the disease is autoimmune disease.